KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent Deferred Tax AssetsCurrent TaxesDividends payablesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pfizer (PFE) Non-Current Assets (2016 - 2025)

Historic Non-Current Assets for Pfizer (PFE) over the last 17 years, with Q3 2025 value amounting to $162.1 billion.

  • Pfizer's Non-Current Assets fell 804.36% to $162.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $662.9 billion, marking a year-over-year decrease of 169.39%. This contributed to the annual value of $3.2 billion for FY2024, which is 711.2% up from last year.
  • According to the latest figures from Q3 2025, Pfizer's Non-Current Assets is $162.1 billion, which was down 804.36% from $162.4 billion recorded in Q2 2025.
  • Pfizer's 5-year Non-Current Assets high stood at $178.7 billion for Q1 2024, and its period low was $3.0 billion during Q4 2023.
  • For the 5-year period, Pfizer's Non-Current Assets averaged around $107.3 billion, with its median value being $129.6 billion (2022).
  • As far as peak fluctuations go, Pfizer's Non-Current Assets plummeted by 1540.84% in 2022, and later skyrocketed by 30054.82% in 2023.
  • Quarter analysis of 5 years shows Pfizer's Non-Current Assets stood at $3.6 billion in 2021, then fell by 15.41% to $3.0 billion in 2022, then decreased by 0.17% to $3.0 billion in 2023, then grew by 7.11% to $3.2 billion in 2024, then soared by 4928.73% to $162.1 billion in 2025.
  • Its last three reported values are $162.1 billion in Q3 2025, $162.4 billion for Q2 2025, and $162.2 billion during Q1 2025.